Intellia Therapeutics Receives Priority Medicines (PRIME) Designation From the European Medicines Agency for NTLA-2002
Intellia Therapeutics, Inc today announced that the European Medicines Agency (EMA) has granted Priority Medicine (PRIME) designation to NTLA-2002 for the treatment of hereditary angioedema (HAE).
NTLA-2002 is an in-vivo CRISPR-based investigational therapy designed to prevent potentially life-threatening swelling attacks in people with HAE.
The PRIME designation was created by the EMA to provide early and proactive support to developers of promising medicines to optimize their development plans and speed up evaluation. The goal is to help patients benefit as early as possible from innovative new therapies that have demonstrated potential to significantly address unmet medical need.
Intellia President and Chief Executive Officer John Leonard M.D, said: “We are very pleased the EMA has granted PRIME designation to NTLA-2002. This designation provides valuable regulatory benefits and highlights the potential of our novel in-vivo gene editing candidate to address an unmet medical need for people living with hereditary angioedema. We look forward to continuing to work closely with the EMA and regulatory agencies around the world to bring this innovative therapy to patients as quickly as possible.”
(Source: Intellia Therapeutics)
